Clinical Trial Update: 42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia [Phase 2]

View source ↗

Summary

Phase 2 trial update for AKB-6548 in chronic kidney disease with anemia; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• AKB-6548

Snippet

Sponsor: Akebia Therapeutics | Conditions: Anemia, Kidney Disease | Phase 2 | Status: COMPLETED | Results posted: 2022-07-01